donepezil Side Effects
Also known as: Aricept
Analysis of 35,138 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
35,138
Death-Related
5,622
16.0% of reports
Hospitalizations
14,136
40.2% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 5,622 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 2,015 |
| FALL | 598 |
| SEPSIS | 387 |
| DYSPNOEA | 363 |
| ASTHENIA | 361 |
| CARDIO-RESPIRATORY ARREST | 345 |
| FATIGUE | 340 |
| DIZZINESS | 333 |
| DIARRHOEA | 315 |
| DECREASED APPETITE | 310 |
| PNEUMONIA | 303 |
| SOMNOLENCE | 287 |
| NAUSEA | 282 |
| HAEMORRHAGIC STROKE | 280 |
| VOMITING | 276 |
| COMA | 267 |
| INSOMNIA | 265 |
| TACHYCARDIA | 264 |
| ALTERED STATE OF CONSCIOUSNESS | 260 |
| COMPLETED SUICIDE | 256 |
Reactions in Hospitalization Reports
Top reactions in 14,136 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FALL | 1,831 |
| CONFUSIONAL STATE | 842 |
| BRADYCARDIA | 753 |
| URINARY TRACT INFECTION | 728 |
| PNEUMONIA | 683 |
| DIARRHOEA | 682 |
| SYNCOPE | 659 |
| ASTHENIA | 647 |
| NAUSEA | 633 |
| VOMITING | 611 |
| DEHYDRATION | 602 |
| DRUG INTERACTION | 593 |
| HYPOTENSION | 577 |
| DIZZINESS | 569 |
| DYSPNOEA | 510 |
| FATIGUE | 484 |
| HALLUCINATION | 465 |
| DEMENTIA | 443 |
| SOMNOLENCE | 438 |
| DECREASED APPETITE | 418 |
Nearby — Related Medications
What the FAERS Data Reveals About donepezil Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 35,138 voluntary reports linked to donepezil and its brand equivalents (Aricept), spanning 2003 through 2025. Of those, 5,622 (16.0%) listed death as an outcome and 14,136 (40.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 54% were female and 46% male; age distribution skews toward 75+, with 16,404 reports in that bracket. The single most reported reaction is fall with 2,965 submissions, followed by death and confusional state.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.